نتائج البحث - Eugene Balagula

  • يعرض 1 - 1 نتائج من 1
تنقيح النتائج
  1. 1
    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-R... حسب Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, C.E.M. Griffiths

    منشور في 2025
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: